conjunctivitis%20-%20allergic,%20seasonal%20-and-%20perennial
CONJUNCTIVITIS - ALLERGIC, SEASONAL & PERENNIAL

Conjunctivitis is the inflammation of the conjunctiva.

Allergic conjunctivitis happens when the direct exposure of the ocular mucosal surfaces to the environment causes an immediate hypersensitivity reaction in which triggering antigens couple to reaginic antibodies (IgE) on the cell surface of mast cells and basophils, leading to the release of histamines that causes capillary dilation and increased permeability and thus conjunctival injection and swelling.
Seasonal allergic conjunctivitis is the most common form of allergic conjunctivitis in temperate climates. It usually occurs and recurs at a certain period of the year (eg summer).
Perennial allergic conjunctivitis manifests and recurs throughout the year with no seasonal predilection. It is most common in tropical climates.

Drug Information

Indication: Symptomatic relief of allergic rhinitis eg, sneezing, nasal discharge & itching, as well as ocular itching...

Indication: Symptomatic treatment of seasonal & perennial allergic rhinitis & urticaria of allergic origin.

Indication: Symptomatic treatment of seasonal & perennial allergic rhinitis & urticaria.

Indication: Relief of symptoms associated w/ allergic rhinitis; symptoms & signs of chronic urticaria & other alle...

Indication: Symptomatic treatment of seasonal rhinitis, perennial allergic rhinitis & urticaria of allergic origin.

Indication: Symptomatic relief of allergic rhinitis, chronic urticaria & other dermatological disorder.

Indication: Symptomatic treatment of seasonal & perennial allergic rhino-conjunctivitis & urticaria.

Indication: Symptomatic relief of allergic rhinitis eg, sneezing, rhinorrhoea & itching, as well as ocular itching &am...

Indication: Symptomatic treatment of seasonal rhinitis, perennial allergic rhinitis & urticaria of allergic origin.

Indication: Symptomatic treatment of seasonal rhinitis, perennial allergic rhinitis & urticaria of allergic origin in ...

1  /  7
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.